Industries
Chemicals & Flavors & Fragrances
All research in Chemicals & Flavors & Fragrances — 3 reports.
40/100
DSM-Firmenich: A Genuine Portfolio Cleanup, Already Priced for the Improvement to Continue
DSM-Firmenich is a Swiss-domiciled flavors, fragrances and health-ingredients platform whose 2025 continuing-operations results (sales of EUR 9.03 billion, adjusted EBITDA of EUR 1.77 billion at a 19.6% margin) show a business getting cleaner as it exits Animal Nutrition & Health to CVC for about EUR 2.2 billion, while Perfumery & Beauty carries the group with 8% like-for-like growth in the first quarter of 2026 even as Taste, Texture & Health and Health, Nutrition & Care remain uneven. Rating Hold: the portfolio has genuinely improved faster than the market expected a year ago, but at EUR 85 the price already reflects a fair share of that cleanup, with the ideal buy zone at EUR 64 to 70.
47/100
Symrise: A High-Quality Compounder Now Priced for Delivery, Not Discovery
Symrise is a scaled, oligopolistic flavors-and-fragrances and nutrition platform that gets paid for being embedded in customers' everyday products, with 2025 sales of €4.93 billion, a 21.9% adjusted EBITDA margin and record €780 million of business free cash flow. The 2026 question is delivery, not discovery: organic growth has cooled from 8.7% in 2024 to low single digits in 2025 and slightly negative in Q1 2026, yet cash conversion, leverage and margin quality all improved, so the franchise is intact while the near-term growth premium is not obviously earned. Rating Hold: a high-quality compounder whose €88.16 price already reflects most of the self-help and recovery, with a more comfortable margin of safety only in the high-€50s to mid-€60s.
45/100
Givaudan SA (GIVN.SW) Zen Horizon Research Report
Givaudan SA (GIVN.SW), headquartered in Geneva and tracing its roots to 1768, is the global leader in flavors and fragrances, with FY2025 revenue of CHF 7,472M, comparable EBITDA margin of 24.2%, and net income of CHF 1,071M. Its two-pillar Fragrance & Beauty plus Taste & Wellbeing business holds roughly 25% global share, while the oligopoly with IFF, Firmenich, and Symrise controls at least 53% of the market, but the key variables are the CEO handover after a 20-year tenure and the Q1 2026 slowdown in Taste. Research rating Watch: a high-quality GDP-plus compounder, but the current price already prices in much of the quality while the CEO transition and Taste deceleration still need evidence.